Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 16 03 2022
accepted: 05 07 2022
pubmed: 19 7 2022
medline: 3 11 2022
entrez: 18 7 2022
Statut: ppublish

Résumé

Data on Device-related Thrombus (DRT) after left atrial appendage closure (LAAC) remain scarce. This study aimed to investigate risk factors for DRT from centers reporting to the EUROC-DRT registry. We included 537 patients (112 with DRT and 425 without DRT) who had undergone LAAC between 12/2008 and 04/2019. Baseline and implantation characteristics, anti-thrombotic treatment and clinical outcomes were compared between both groups in uni- and multivariate analyses. Additional propensity-score matching (PSM) was conducted to focus on the role of implantation characteristics. Patients with DRT showed higher rates of previous stroke/transient ischemic attack (TIA) (49.1% vs. 34.7%, p < 0.01), spontaneous echocardiographic contrast (SEC) (44.9% vs. 27.7%, p < 0.01) and lower left atrial appendage (LAA) peak emptying velocity (35.4 ± 18.5 vs. 42.4 ± 18.0 cm/s, p = 0.02). Occluders implanted in DRT patients were larger (25.5 ± 3.8 vs. 24.6 ± 3.5 mm, p = 0.03) and implanted deeper in the LAA (mean depth: 7.6 ± 4.7 vs. 5.7 ± 4.7 mm, p < 0.01). Coverage of the appendage ostium was achieved less often in DRT patients (69.5% vs. 81.5%, p < 0.01), while DRT patients were less frequently on oral anticoagulation (7.1% vs. 16.7%, p < 0.01). Multivariate analysis identified age, prior stroke/TIA and SEC as independent risk factors for DRT. After PSM, implantation depth was found to be predictive. Rates of stroke/TIA were higher in DRT patients (13.5% vs. 3.8%, Hazard Ratio: 4.21 [95%-confidence interval: 1.88-9.49], p < 0.01). DRT after LAAC is associated with adverse outcome and appears to be of multifactorial origin, depending on patient characteristics, anticoagulation regimen and device position.

Sections du résumé

BACKGROUND BACKGROUND
Data on Device-related Thrombus (DRT) after left atrial appendage closure (LAAC) remain scarce. This study aimed to investigate risk factors for DRT from centers reporting to the EUROC-DRT registry.
METHODS METHODS
We included 537 patients (112 with DRT and 425 without DRT) who had undergone LAAC between 12/2008 and 04/2019. Baseline and implantation characteristics, anti-thrombotic treatment and clinical outcomes were compared between both groups in uni- and multivariate analyses. Additional propensity-score matching (PSM) was conducted to focus on the role of implantation characteristics.
RESULTS RESULTS
Patients with DRT showed higher rates of previous stroke/transient ischemic attack (TIA) (49.1% vs. 34.7%, p < 0.01), spontaneous echocardiographic contrast (SEC) (44.9% vs. 27.7%, p < 0.01) and lower left atrial appendage (LAA) peak emptying velocity (35.4 ± 18.5 vs. 42.4 ± 18.0 cm/s, p = 0.02). Occluders implanted in DRT patients were larger (25.5 ± 3.8 vs. 24.6 ± 3.5 mm, p = 0.03) and implanted deeper in the LAA (mean depth: 7.6 ± 4.7 vs. 5.7 ± 4.7 mm, p < 0.01). Coverage of the appendage ostium was achieved less often in DRT patients (69.5% vs. 81.5%, p < 0.01), while DRT patients were less frequently on oral anticoagulation (7.1% vs. 16.7%, p < 0.01). Multivariate analysis identified age, prior stroke/TIA and SEC as independent risk factors for DRT. After PSM, implantation depth was found to be predictive. Rates of stroke/TIA were higher in DRT patients (13.5% vs. 3.8%, Hazard Ratio: 4.21 [95%-confidence interval: 1.88-9.49], p < 0.01).
CONCLUSIONS CONCLUSIONS
DRT after LAAC is associated with adverse outcome and appears to be of multifactorial origin, depending on patient characteristics, anticoagulation regimen and device position.

Identifiants

pubmed: 35849156
doi: 10.1007/s00392-022-02065-4
pii: 10.1007/s00392-022-02065-4
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1276-1285

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Hildick-Smith D, Landmesser U, Camm AJ et al (2020) Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Eur Heart J 41:2894–2901. https://doi.org/10.1093/eurheartj/ehaa169
doi: 10.1093/eurheartj/ehaa169 pubmed: 32243499 pmcid: 7421773
Holmes DR, Reddy VY, Turi ZG et al (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534–542. https://doi.org/10.1016/S0140-6736(09)61343-X
doi: 10.1016/S0140-6736(09)61343-X pubmed: 19683639
Cochet H, Iriart X, Sridi S et al (2018) Left atrial appendage patency and device-related thrombus after percutaneous left atrial appendage occlusion: a computed tomography study. Eur Heart J Cardiovasc Imaging 19:1351–1361. https://doi.org/10.1093/ehjci/jey010
doi: 10.1093/ehjci/jey010 pubmed: 29415203
Fauchier L, Cinaud A, Brigadeau F et al (2018) Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol 71:1528–1536. https://doi.org/10.1016/j.jacc.2018.01.076
doi: 10.1016/j.jacc.2018.01.076 pubmed: 29622159
Lempereur M, Aminian A, Saw J (2018) Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv 92:E216–E217. https://doi.org/10.1002/ccd.27135
doi: 10.1002/ccd.27135 pubmed: 28544491
Sedaghat A, Schrickel J, Andrié R et al (2016) Thrombus formation after left atrial appendage occlusion with the amplatzer amulet device. JACC Clin Electrophysiol. https://doi.org/10.1016/j.jacep.2016.05.006
doi: 10.1016/j.jacep.2016.05.006 pubmed: 29759698
Dukkipati SR, Kar S, Holmes DR et al (2018) Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation 138:874–885. https://doi.org/10.1161/CIRCULATIONAHA.118.035090
doi: 10.1161/CIRCULATIONAHA.118.035090 pubmed: 29752398
Sedaghat A, Nickenig G, Schrickel JW et al (2021) Incidence, predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device-Insights from the EWOLUTION real world registry. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. https://doi.org/10.1002/ccd.29458
doi: 10.1002/ccd.29458
Freixa X, Cepas-Guillen P, Flores-Umanzor E et al (2021) Pulmonary ridge coverage and device-related thrombosis after left atrial appendage occlusion. EuroIntervention 16:E1288–E1294. https://doi.org/10.4244/EIJ-D-20-00886
doi: 10.4244/EIJ-D-20-00886 pubmed: 33164895
Sedaghat A, Vij V, Al-Kassou B et al (2021) Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ Cardiovasc Interv. https://doi.org/10.1161/circinterventions.120.010195
doi: 10.1161/circinterventions.120.010195 pubmed: 34003661
Aminian A, Schmidt B, Mazzone P et al (2019) Incidence, characterization, and clinical impact of device-related thrombus following left atrial appendage occlusion in the prospective global AMPLATZER amulet observational study. JACC Cardiovasc Interv 12:1003–1014. https://doi.org/10.1016/j.jcin.2019.02.003
doi: 10.1016/j.jcin.2019.02.003 pubmed: 31103540
Pracon R, Bangalore S, Dzielinska Z et al (2018) Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy. Circ Cardiovasc Interv 11:1–7. https://doi.org/10.1161/CIRCINTERVENTIONS.117.005997
doi: 10.1161/CIRCINTERVENTIONS.117.005997
Simard T, Jung RG, Lehenbauer K et al (2021) Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol 78:297–313. https://doi.org/10.1016/j.jacc.2021.04.098
doi: 10.1016/j.jacc.2021.04.098 pubmed: 34294267
Plicht B, Konorza TFM, Kahlert P et al (2013) Risk factors for thrombus formation on the amplatzer cardiac plug after left atrial appendage occlusion. JACC Cardiovasc Interv 6:606–613. https://doi.org/10.1016/j.jcin.2013.02.014
doi: 10.1016/j.jcin.2013.02.014 pubmed: 23787233
Rashid HN, Layland J (2021) Association between device-related thrombus and the neo-appendage with left-atrial appendage occlusion devices. Eur Heart J 42:1047–1048. https://doi.org/10.1093/eurheartj/ehaa803
doi: 10.1093/eurheartj/ehaa803 pubmed: 33167004
Mill J, Olivares AL, Arzamendi D et al (2020) Impact of flow dynamics on device-related thrombosis after left atrial appendage occlusion. Can J Cardiol 36:968.e13-968.e14. https://doi.org/10.1016/j.cjca.2019.12.036
doi: 10.1016/j.cjca.2019.12.036
Meier B (2018) What lies beneath left atrial appendage occlusion. Circulation 11:1–3. https://doi.org/10.1161/CIRCINTERVENTIONS.118.006360
doi: 10.1161/CIRCINTERVENTIONS.118.006360
Søndergaard L, Wong YH, Reddy VY et al (2019) Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv 12:1055–1063. https://doi.org/10.1016/j.jcin.2019.04.004
doi: 10.1016/j.jcin.2019.04.004 pubmed: 31171282
Duthoit G, Silvain J, Marijon E et al (2020) Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study. Circ Cardiovasc Interv 13:e008481. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008481
doi: 10.1161/CIRCINTERVENTIONS.119.008481 pubmed: 32674675
Garot P, Iriart X, Aminian A et al (2020) Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study. Open Hear 7:1–5. https://doi.org/10.1136/openhrt-2020-001326
doi: 10.1136/openhrt-2020-001326

Auteurs

Vivian Vij (V)

Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Kerstin Piayda (K)

CardioVasculäres Centrum, Frankfurt, Germany.

Dominik Nelles (D)

Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Steffen Gloekler (S)

University Hospital Bern, Bern, Switzerland.

Roberto Galea (R)

University Hospital Bern, Bern, Switzerland.

Monika Fürholz (M)

University Hospital Bern, Bern, Switzerland.

Bernhard Meier (B)

University Hospital Bern, Bern, Switzerland.

Marco Valgimigli (M)

University Hospital Bern, Bern, Switzerland.
Cardiocentro Ticino, Lugano, Switzerland.

Gilles O'Hara (G)

Quebec Heart & Lung Institute, Laval University, Quebec City, Canada.

Dabit Arzamendi (D)

Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Victor Agudelo (V)

Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Lluis Asmarats (L)

Quebec Heart & Lung Institute, Laval University, Quebec City, Canada.
Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.

Xavier Freixa (X)

Hospital Clinic Barcelona, Barcelona, Spain.

Eduardo Flores-Umanzor (E)

Hospital Clinic Barcelona, Barcelona, Spain.

Ole De Backer (O)

Rigshospitalet, Copenhagen University Hospital Copenhagen, København, Denmark.

Lars Sondergaard (L)

Rigshospitalet, Copenhagen University Hospital Copenhagen, København, Denmark.

Luis Nombela-Franco (L)

Hospital Clinico San Carlos Madrid, Madrid, Spain.

Angela McInerney (A)

Hospital Clinico San Carlos Madrid, Madrid, Spain.

Kasper Korsholm (K)

Aarhus University Hospital, Aarhus, Denmark.

Jens Erik Nielsen-Kudsk (JE)

Aarhus University Hospital, Aarhus, Denmark.

Shazia Afzal (S)

University Hospital Düsseldorf, Düsseldorf, Germany.

Tobias Zeus (T)

University Hospital Düsseldorf, Düsseldorf, Germany.

Felix Operhalski (F)

Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany.

Boris Schmidt (B)

Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany.

Gilles Montalescot (G)

Surbonne University Pitié-Salpêtrière Hospital (AP-HP), Paris, France.

Paul Guedeney (P)

Surbonne University Pitié-Salpêtrière Hospital (AP-HP), Paris, France.

Xavier Iriart (X)

University Hospital Bordeaux, Bordeaux, France.

Noelie Miton (N)

University Hospital Bordeaux, Bordeaux, France.

Jacqueline Saw (J)

Vancouver General Hospital, Vancouver, Canada.

Thomas Gilhofer (T)

Stadtspital Waid and Triemli, Zurich, Switzerland.

Laurent Fauchier (L)

University Hospital Tours, Tours, France.

Egzon Veliqi (E)

St. Georg Hospital Hamburg, Hamburg, Germany.

Felix Meincke (F)

St. Georg Hospital Hamburg, Hamburg, Germany.

Nils Petri (N)

University Hospital Würzburg, Würzburg, Germany.

Peter Nordbeck (P)

University Hospital Würzburg, Würzburg, Germany.

Dmitrii Ognerubov (D)

Russian Cardiology Research and Production Complex, Moscow, Russia.

Evgeny Merkulov (E)

Russian Cardiology Research and Production Complex, Moscow, Russia.

Ignacio Cruz-González (I)

University Hospital of Salamanca, CIBER CV, IBSAL, Salamanca, Spain.

Rocio Gonzalez-Ferreiro (R)

University Hospital of Salamanca, CIBER CV, IBSAL, Salamanca, Spain.

Deepak L Bhatt (DL)

Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, USA.

Alessandra Laricchia (A)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Humanitas Research Hospital IRCCS, Rozzano, Italy.

Antonio Mangieri (A)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Humanitas Research Hospital IRCCS, Rozzano, Italy.

Heyder Omran (H)

Marienkrankenhaus, Bonn, Germany.

Jan Wilko Schrickel (JW)

Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Josep Rodes-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Canada.

Horst Sievert (H)

CardioVasculäres Centrum, Frankfurt, Germany.

Georg Nickenig (G)

Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Alexander Sedaghat (A)

Department of Cardiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Alexander.sedaghat@ukbonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH